Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors

被引：36

作者：

Cheng, Kang ^{[1
]}

Liu, Chen-Fu ^{[2
]}

Rao, Guo-Wu ^{[1
]}

机构：

[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China

[2] Gannan Med Univ, Sch Pharmaceut Sci, Ganzhou 341000, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2021年 / 28卷 / 13期

关键词：

Tumor; anti-angiogenic agents; tyrosine kinase; VEGFR-2; inhibitor; approved drugs; synthesis; TYROSINE KINASE INHIBITOR; SMALL-MOLECULE INHIBITORS; RENAL-CELL CARCINOMA; DOUBLE-BLIND; PHASE-I; SIMULTANEOUS BLOCKADE; ANTITUMOR EVALUATION; PONATINIB AP24534; STROMAL TUMOR; CANCER;

D O I：

10.2174/0929867327666200514082425

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of drug development and chemical synthesis.

引用

页码：2540 / 2564

页数：25

共 50 条

[1] Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
Falcon, Beverly L.
Chintharlapalli, Sudhakar
Uhlik, Mark T.
Pytowski, Bronislaw
[J]. PHARMACOLOGY & THERAPEUTICS, 2016, 164 : 204 - 225
[2] Vascular endothelial growth factor receptor-2 (VEGFR-2) N-glycosylation modulates angiogenic signaling
Chandler, Kevin B.
Leon, Deborah R.
Meyer, Rosana D.
Rahimi, Nader
Costello, Catherine E.
[J]. CANCER RESEARCH, 2017, 77
[3] Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy
Underiner, TL
Ruggeri, B
Gingrich, DE
[J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (06) : 731 - 745
[4] Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy
Veeravagu, Anand
Hsu, Andrew R.
Cai, Weibo
Hou, Lewis C.
Tse, Victor C. K.
Chen, Xiaoyuan
[J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (01) : 59 - 71
[5] Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity
Alam, A
Herault, JP
Barron, P
Favier, B
Fons, P
Delesque-Touchard, N
Senegas, I
Laboudie, P
Bonnin, J
Cassan, C
Savi, P
Ruggeri, B
Carmeliet, P
Bono, FO
Herbert, JM
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) : 909 - 915
[6] In-silico screening and In-vitro validation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) inhibitors
Saraswat, Deepika
Nehra, Sarita
Chaudhary, Kamal Kumar
Prasad, C. V. S. Siva
[J]. BIOINFORMATION, 2014, 10 (05) : 273 - 280
[7] Cellular expression of vascular endothelial growth factor receptor-2 (VEGFR-2) indicates potential non-angiogenic roles for VEGFR-2 in spermatogenesis and ovulation in VEGFR-2 lacZ mice.
Clopton, DT
Bott, RC
McFee, RM
Cupp, AS
[J]. BIOLOGY OF REPRODUCTION, 2004, : 244 - 244
[8] Vascular endothelial growth factor receptor-2 ( VEGFr-2) genetic polymorphisms as predictors to antiangiogenic therapy
Jurado, J., Sr.
Ortega, J. A.
Iglesias, P.
Garcia-Puche, J. L.
Belon, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[9] Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening
Chelliah, Selvam
Mock, Charlotta D.
Mathew, Omana P.
Ranganna, Kasturi
[J]. FASEB JOURNAL, 2018, 32 (01):
[10] Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins
Gingras, D
Lamy, S
Béliveau, R
[J]. BIOCHEMICAL JOURNAL, 2000, 348 : 273 - 280

← 1 2 3 4 5 →